Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details Textual)

v3.10.0.1
Summary of Significant Accounting Policies (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 09, 2015
Feb. 21, 2017
Dec. 31, 2018
Jan. 01, 2019
Jan. 02, 2018
Dec. 31, 2017
Money Market Funds Fair Value     $ 0     $ 750,965
Contingent Consideration Funds Fair Value     1,210,000     1,210,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     3,912,314      
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets         $ 9,500,000  
Contract with Customer, Liability, Revenue Recognized     9,627,600      
Intangible Assets and Inprocess Research And Development     243,750      
Restricted Cash and Cash Equivalents, Noncurrent     45,000     45,000
Goodwill     1,525,896     1,525,896
Deferred Tax Liabilities, Net     $ 269,968     $ 183,923
Right of use Assets Beginning Balance       $ 137,000    
New Accouting Pronouncements Corresponding Liabilities Balance       $ 137,000    
Maximum [Member]            
Property, Plant and Equipment, Useful Life     5 years      
Minimum [Member]            
Property, Plant and Equipment, Useful Life     2 years      
New Valeant Agreement [Member]            
Revenues Recognition Milestone Method Description   Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field.        
Proceeds From Upfront Payment $ 1,000,000 $ 4,000,000        
Contract with Customer, Liability, Revenue Recognized 32,500,000 99,000,000        
Revenue Recognition Milestone Payments $ 5,400,000 $ 3,400,000        
Jade Therapeutic sInc [Member]            
Goodwill     $ 1,525,896